During this video interview from UroToday, Dr Tian Zhang from the Duke Cancer Centre in North Carolina, USA talks about the PDIGREE trial and the effect of the COVID-19 pandemic on the trial.
PDIGREE is a novel adaptive study which will help answer many important questions, such as treatment duration, when to use vascular endothelial growth factor (VEGF) inhibitor TKI treatment with immunotherapy, and which patients benefit most from this combination in the first-line versus using it as a sequence.
This trial is actively enrolling patients at US study sites. Patients enrolled in the trial are treated with a combination of ipilimumab and nivolumab every three weeks for four cycles. Following this induction period, patients with a complete response proceed with maintenance nivolumab, and those with a partial response are randomised to nivolumab or nivolumab and cabozantinib. Dr. Zhang discusses the protocol modifications that were made to the trial following the onset of the COVID-19 pandemic.